Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.

Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J, AME Thoracic Surgery Collaborative Group. · 2018

Read Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial. by Yang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J, AME Thoracic Surgery Collaborative Group. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6145832.txt.

Introduction

Yang and co-authors report a phase III clinical trial in Journal of Clinical Oncology on esophageal cancer treatment. The trial, called NEOCRTEC5010, tested chemoradiotherapy given before surgery. The cancer was locally advanced squamous cell carcinoma of the esophagus. Whether the added treatment helps was still controversial.

From 2007 to 2014, 451 patients were randomly assigned to chemoradiotherapy plus surgery or surgery alone. The combined group also received the drugs vinorelbine and cisplatin with radiation. The combined treatment raised both overall survival and disease-free survival. Side effects were tracked as well. The trial supports the combined approach for patients whose tumors can still be removed.

Catalog record

CREATORYang H, Liu H, Chen Y, Zhu C, Fang W, Yu Z, Mao W, Xiang J, Han Y, Chen Z, Yang H, Wang J, Pang Q, Zheng X, Yang H, Li T, Lordick F, D'Journo XB, Cerfolio RJ, Korst RJ, Novoa NM, Swanson SJ, Brunelli A, Ismail M, Fernando HC, Zhang X, Li Q, Wang G, Chen B, Mao T, Kong M, Guo X, Lin T, Liu M, Fu J, AME Thoracic Surgery Collaborative Group.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE32 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6145832

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial By Hong Yang, Hui Liu, Yuping Chen, Chengchu Zhu, Wentao Fang, Zhentao Yu, Weimin Mao, Jiaqing Xiang, Yongtao Han, Zhijian Chen, Haihua Yang, Jiaming Wang Published in: Journal of Clinical Oncology DOI: 10.1200/JCO.2018.79.1483 ABSTRACT Purpose The efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. In this trial, we compared the survival and safety of NCRT plus surgery with surgery alone in patients with locally advanced ESCC. Patients and Methods From June 2007 to December 2014, 451 patients with potentially resectable thoracic ESCC, clinically staged as T1-4N1M0/T4N0M0, were randomly allocated to NCRT plus surgery (group CRT; n = 224) and surgery alone (group S; n = 227). In group CRT, patients received vinorelbine 25 mg/m2 intravenously (IV) on days 1 and 8 and cisplatin 75 mg/m2 IV day 1, or 25 mg/m2 IV on days 1 to 4 every 3 weeks for two cycles, with a total concurrent radiation dose of 40.0 Gy administered in 20 fractions of 2.0 Gy on 5 days per week. In both groups, patients underwent McKeown or Ivor Lewis esophagectomy. The primary end point was overall survival. Results The pathologic complete response rate was 43.2% in group CRT. Compared with group S, group CRT had a higher R0 resection rate (98.4% v 91.2%; P = .002), a better median overall survival (100.1 months v 66.5 months; hazard ratio, 0.71; 95% CI, 0.53 to 0.96; P = .025), and a prolonged disease-free survival (100.1 months v 41.7 months; hazard ratio, 0.58; 95% CI, 0.43 to 0.78; P < .001). Leukopenia (48.9%) and neutropenia (45.7%) were the most common grade 3 or 4 adverse events during chemoradiotherapy. Incidences of postoperative complications were similar between groups, with the exception of arrhythmia (group CRT: 13% v group S: 4.0%; P = .001). Peritreatment mortality was 2.2% in group CRT versus 0.4% in group S (P = .212). Conclusion This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events. INTRODUCTION Esophageal cancer (EC) is the sixth most common cancer worldwide.1 China has a high prevalence of EC that accounts for > 50% of the global morbidity and mortality.2 More than 90% of patients with EC in China have esophageal squamous cell carcinoma (ESCC). After surgery alone, the prognosis for patients with locally advanced EC remains poor, with a 5-year survival rate of only 25%.3 Recent evidence has suggested a survival benefit from neoadjuvant concurrent chemoradiotherapy followed by surgery.4 However, the results from randomized controlled trials comparing neoadjuvant chemoradiotherapy (NCRT) followed by surgery with surgery alone have been inconsistent.5-13 Moreover, most studies were conducted in Western countries,5-12 which have a high prevalence of esophagogastric junction adenocarcinoma. The sample size of ESCC was relatively small in most trials5-11; there were usually no more than 80 cases of patients with ESCC receiving NCRT in each study.5-13 Whether the results could be applied to East Asian countries such as China where the incidence of ESCC is extremely high remains to be elucidated. A well-designed, large-scale, randomized control trial is needed to evaluate the usefulness of NCRT for ESCC. The current phase III trial enrolled patients with locally advanced ESCC. The primary goal was to compare the survival benefit of NCRT plus surgery versus surgery alone in locally advanced ESCC. PATIENTS AND METHODS Eligibility Eligible patients had histologically confirmed, potentially resectable thoracic ESCC clinically staged as T1-4N1M0/T4N0M0 (stage IIB or III) before treatment14; were 18 to 70 years of age; had normal hematologic, renal, and hepatic function; and had a Karnofsky performance score of ≥ 90. We excluded patients with a history of other malignancies; those who were unsuitable for surgery because of comorbidities; those for whom reconstruction with stomach conduit was infeasible because of prior gastrectomy; and those unable to sign informed consent because of psychological, family, or social reasons (Appendix, online only). Approval was obtained from the ethics committee or institutional review board at each center. All included patients provided written informed consent. Random Assignment Patients were randomly assigned in a 1:1 ratio, using a stratified permuted-block method, to receive NCRT followed by surgery (group CRT) or surgery alone (group S) and were stratified according to coordinating centers. Random assignment was generated by computer-generated random assignment lists at the Sun Yat-sen University Cancer Center Clinical Trial Center. The assignments were placed in sealed envelopes, labeled by stratum, which would only be unsealed after patient registration. Permuted-block size was 20. Investigators at each center enrolled participants and assigned them to interventions. Pretreatment Workup and Staging All patients received the following pretreatment examinations and staging: neck, thorax, and abdomen plain and contrast-enhanced computed tomography (CT); esophagogastroduodenoscopy, with ultrasound endoscopy (EUS); and cervical ultrasonography. If indicated, bronchoscopy was performed to exclude tumor infiltration into the trachea or bronchial tree. Positron emission tomography and radionuclide bone imaging were optional. Preoperative Chemoradiotherapy For patients assigned to group CRT, vinorelbine 25 mg/m2, intravenous (IV) bolus, days 1 and 8 and cisplatin 75 mg/m2, IV within 3 hours, day 1; or 25 mg/m2, IV within 2 hours on days 1 to 4 were administered every 3 weeks for two cycles. A total dose of 40.0 Gy was administered in 20 fractions of 2.0 Gy, five fractions per week, starting at the first day of the first cycle of chemotherapy. All patients were radiated by external beam radiation, using the three-dimensional conformal radiation technique. Radiation therapy was delivered with megavoltage equipment with photon energies of 6 to 8 MV. The gross tumor volume was defined by the primary tumor and any enlarged regional lymph nodes, which were determined using all available information (physical examination, endoscopy, EUS, neck-thorax-abdomen CT). The clinical target volume provided a proximal and distal margin of 3 cm and a 0.5- to 1.0-cm radial margin around the gross tumor volume to include the area of subclinical involvement. The planning target volume was defined as an 8-mm margin of the clinical target volume for tumor motion and set-up variations. A detailed description of the methods of chemotherapy and radiotherapy can be found in the protocol. Dose reductions and delays of chemotherapy, and interruptions of radiotherapy, were specified in the protocol (Appendix Table A1, online only). Briefly, full-dose chemotherapy was administered if the absolute neutrophil count was > 1.5 × 109/L and the platelet count was ≥ 75 × 109/L. If not, chemotherapy was delayed for up to 2 weeks until the counts recovered. The second cycle of chemotherapy was discontinued if hematologic toxicity persisted for longer than 2 weeks. Approximately 4 to 6 weeks after the completion of chemoradiotherapy, patients underwent clinical restaging including physical examination, standard laboratory tests, esophagogastroduodenoscopy with EUS, pulmonary function tests, esophageal barium x-ray, and neck-thorax-abdomen CT. Surgery In group CRT, surgery was scheduled for 4 to 6 weeks after completion of chemoradiotherapy. For patients in group S, surgery was performed as soon as possible after random assignment. McKeown or Ivor Lewis esophagectomy, including two-field lymphadenectomy with total mediastinal lymph node dissection, was performed. The dissection of

Read the complete text